Synthesis, characterization and antitumor activities of a series of platinum(II) complexes with 1R,3S-1,2,2-trimethylcyclopentanediamine

Chinese Journal of Inorganic Chemistry

Volumn 20, Issue 7, 2004, Pages 775-780

  Wang, Lian Hong ^a,b   Liu, Yun ^b   Yuan, Fu Ping ^b   You, Qi Dong ^a   Guo, Shao Hua ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

1R,3S 1,2,2 trimethylcyclopentanediamine; Antitumor activity; Chiral ligand; Classical structure activity relationships; Platinum (II) complexes

Indexed keywords

CYCLOPENTANE DERIVATIVE; DIAMINE DERIVATIVE; PLATINUM COMPLEX;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN; CHIRALITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG SYNTHESIS; ELECTRON SPIN RESONANCE; HUMAN; HUMAN CELL; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; THERMAL ANALYSIS;

EID: 3042803633     PISSN: 10014861     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Rosenberg B., VanCamp L., Trosko J. E., Mansour V. H. Nature, 1969,222,385.
2. William S. D., Einhorn L. H. In Cisplatin: Current, Status and New Developments, Academic Press: New York, 1980.
3. Rosenberg B. Cancer Treat. Rep., 1979,63,1433.
4. Loehrer P. J., Einhorn L. H. Ann. Intern. Med., 1984,100, 704.
5. Soloway M. S. J. Urol., 1978,120,716.
6. Harrap K. J. Cancer Treat. Rev., 1985,12,21.
7. Duffull S. B., Robinson B. A. Clin Pharmacokinet., 1997,33, 161.
8. Gore M., Fryatt I., Wiltshawk E., Dawson T., Robinson B., Calvert A. Br. J. Cancer, 1989,60,767.
9. Wong E., Giandomenico C. M. Chem. Rev., 1999,99,2451.
10. O'Neill C. F., Koberle B., Masters J. R. W., Kelland L. R. Br. J. Cancer, 1999,81,1294.
11. Bednarski P. Curr. Opin. Oncol., Endocr. Metab. Invest. Drugs, 1999,1,448.
12. Holford J., Beale P. J., Boxall F. E. Eur. J. Cancer, 2000, 36,1984.
13. Kelland L. R., Barnard C. F. J., Mellish K. J., Jones, M., Goddard P. M., Valenti M., Bryant A. Cancer Res., 1994, 54,5618.
14. Lemma K., Shi T., Elding L. I. Inorg. Chem., 2000,39,1728.
15. Kloster M. B. G., Hannis J. C., Muddiman D. C. Biochem., 1999,38,14731.
16. Davies M. S., Thomas D. S., Hegmans A. Inorg. Chem., 2002, 41,1101.
17. Amtmann E., Zoller M., Wesch H. Cancer Chemother. Pharmacol., 2001,47,461.
18. Fukuda M., Shinkai T., Eguchi K., Sasaki Y., Tamura T., Ohe Y., Kojima A., Oshita F., Hara K., Saijo N. Cancer Chemother. Pharmacol., 1990,26,393.
19. Andrew S. E. Curr. Opin. Oncol., Endocr. Metab. Invest. Drugs, 2000,2,339.
20. McKeage M. J. Expert Opin. Invest. Drugs, 2001,10,119.
21. WANG Lian-Hong, LIU Yun, GOU Shao-Hua, YOU Qi-Dong Huaxue Tongbao(Acta Chem.), 2003,66,828.
22. TAO Rong-Da Huaxue Shijie(Chem. World), 1997, (11),566.
23. QU Jun, TANG Wen-Xia, DAI An-Bang, JI Xiu-Juan, ZHANG Fu-Rong, LIU Xiao-Mei Wuji Huaxue (Chinese J. Inorg. Chem.), 1988,4(2),90.
24. Suszko J., Trzebniak F. Roczniki Chem., 1937,17,105.